Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
September 05, 2023 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel...
IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus
August 24, 2023 16:05 ET
|
Imunon, Inc.
CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidates in animal models LAWRENCEVILLE, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
August 14, 2023 08:30 ET
|
Imunon, Inc.
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference
August 10, 2023 16:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 08:00 ET
|
Imunon, Inc.
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at...
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
August 01, 2023 09:00 ET
|
SciSparc Ltd
TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and...
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
July 11, 2023 08:15 ET
|
Purple Biotech Ltd.
Purple’s innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3rd line PDAC patientsRandomized Phase 2 study is enrolling as expected with initial Phase 2...
Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation
June 29, 2023 08:05 ET
|
Semper Paratus Acquisition Corporation
Tevogen Bio Inc. (“Tevogen Bio”) is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and...
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
June 28, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal...